132235-65-5

Upstream product

• 108267-97-6 (2S,3R)-4-(p-bromobenzyloxy)-2,3-epoxybutan-1-ol 
• 1730-25-2 allylmagnesium bromide 
• 108267-97-6 (2S,3R)-3-<<(4-bromobenzyl)oxy>methyl>oxirane-2-methanol 

Downstream Products

• 132235-67-7 (2S,3R)-4-O-benzoyl-1-O-(p-bromobenzyl)-3-(2'-propenyl)-1,2,4-butanetriol 
• 143563-93-3 methyl 5-O-benzoyl-3-C-<(benzoyloxy)methyl>-2,3-dideoxy-D-erythro-pentofuranoside 
• 143563-19-3 methyl 3-C-<(benzoyloxy)methyl>-5-O-(p-bromobenzyl)-2,3-dideoxy-D-erythro-pentofuranoside 
• 132235-78-0 C₂₅H₂₃N₅O₅ 
• 132235-77-9 C₂₅H₂₃N₅O₅ 
• 152732-95-1 9-(6-O-benzoyl-4-C-benzoyloxymethyl-2,3,4-trideoxy-β-D-erythro-hexopyranosyl)-6-chloropurine 
• 152732-92-8 1-(2,3,4-trideoxy-4-C-benzoyloxymethyl-6-O-benzoyl-β-D-erythro-hexopyranosyl)uracil 
• 152732-86-0 (2S,3R)-4-O-benzoyl-1-O-(4-bromobenzyl)-2-O-tert-butyldimethylsilyl-3-(3-hydroxypropyl)-1,2,4-butanetriol 
• 152732-87-1 (4R,5S)-4-benzoyloxymethyl-6-(4-bromobenzyloxy)-5-tert-butyldimethyl-silyloxy-1-hexanal 
• 152732-85-9 (2S,3R)-4-O-benzoyl-1-O-(4-bromobenzyl)-2-O-tert-butyldimethylsilyl-3-(2-propenyl)-1,2,4-butanetriol 
• 143563-95-5 Methyl 5-O-benzoyl-3-C-<(benzoyloxy)methyl>-2,3-dideoxy-L-threo-pentofuranoside 
• 154819-67-7 (2R,3R)-1-O-(p-Bromobenzyl)-3-(2'-propenyl)-1,2,4-butanetriol 

Relevant academic research and scientific papers

Synthesis of 4-C-hydroxymethyl hexopyranosyl nucleosides as potential inhibitors of HIV

The synthesis of 1-(2,3,4-trideoxy-4-C-hydroxymethyl-β-D-erythro-hexopyranosyl)thymine (13); -uracil (15), -cytosine (16) and 9-(2,3,4-trideoxy-4-C-hydroxymethyl-β-D-erythro-hexopyranosyl)adenine (18) are described. The nucleoside analogues were evaluated

Nucleosides and nucleotide analogues, pharmaceutical composition and processes for the preparation of the compounds

A compound of the formula STR1 wherein the radicals A, X, R1, R2 and R3 are defined as follows: STR2 R2 : H; or R2 constitutes together with R3 with a carbon - carbon bond R3 : H; F; Cl; Br; I; N3 ; CN; C CH; OH; OCH3 ; CH2 OH; and when R3 is F; Cl; Br; I; N3 ; CN; C CH; OH; OCH3 or CH2 OH it may have either the cis-configuration or trans-configuration relative to the hydroxymethyl function at position 4', or R3 constitutes together with R2 a carbon - carbon bond, and therapeutically acceptable salts thereof, for use in therapy, in particular for the treatment of HIV infections.